PHEMOPNCT06361641
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
StatusRecruiting
PhaseNot applicable
SponsorUniversity Hospital, Angers
Primary completion (estimated)
At risk: Primary completion moved at least 6 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Nov 19, 2026 to May 29, 2027
- Eligibility criteria expanded, about 8 words
- Study completion pushed from Nov 19, 2028 to May 29, 2029
- Secondary endpoints: details revised at 2 of 7 entries
- Minor Primary completion pushed from Oct 19, 2026 to Nov 19, 2026
- Study completion pushed from Oct 19, 2028 to Nov 19, 2028
- Notable Primary completion date: Oct 19, 2025 to Oct 19, 2026
- Study completion date: Oct 19, 2027 to Oct 19, 2028
- Minor Enrollment target: 50 to 70
- Site contacts updated at 3 of 3 sites
- Minor Site details revised at 3 of 3 sitesv4
Show 2 earlier versionsHide 2 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised at 3 of 3 sites
- Notable Start date: Apr 20, 2024 to May 29, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
WHO 2016 criteria for polycythemia vera, prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis
Timeframe: Day 0
Secondary (7)
Identify correlation between the monocytic signature and driver mutations (mutation in JAK2, CALR or MPL gene).
Identify correlation between the monocytic signature and the grade of fibrosis
prognostic value of the monocytic signature using a principal component analysis Response criteria according to Barosi et al., Leukemia, vol. 29,1 (2015): 20-6
Prognostic value of the monocyte signature for disease worsening according to Sureau et al., Blood Cancer Journal, vol. 12,4, 56. 8 Apr. 2022
leukemia-free survival
Show 2 moreShow less
myelofibrosis-free survival
Monocytes parameters for hematological progression
Arms and interventions
Phemop CohortExperimental
Diagnostic tests: Monocytes signatures in myeloproliferative neoplasms at diagnosis
Sites
3 sites in 1 country